Publications

The results of the joined research within EuMyoNet/MyoNet can be scientific publications in peer reviewed journals, dissertations and other kind of dissemination material.​

If your are interested in other kind of information created within our research activities, please click on the Activities menu above.​

ESF visibility (from RNP guidelines 2011)​

To ensure visibility of the RNP in supporting publicity, websites and publications, the authors should clearly identify such productions as being ESF-funded or co-funded activities, e.g. in announcements, books, abstracts, etc. ESF member organisations (Mos) contributing to the activity should also be credited in relevant publications. The ESF logo (see logotypes for download) , remit and acknowledgement text for inclusion in such material can be made available by ESF upon request. A copy of any article or publication resulting from an ESF-sponsored activity should be sent to ESF.

​Suggested acknowledgement text could be: “The work reported on in this publication has been financially supported by the European Science Foundation (ESF), in the framework of the Research Networking Programme European Myositis Network (EuMyoNet).

​List of publications

1. Chinoy H, Adimulam S, Marriage F, New P, Vincze M, Zilahi E, Kapitány A, Gyetvai A, Ekholm L, Novota P, Remakova M, Charles P, McHugh NJ, Padyukov L, Alfredsson L, Vencovsky J, Lundberg IE, Danko K, Ollier WE, Cooper RG. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. . Ann Rheum Dis. 2011 Dec 20.

Abstract:

OBJECTIVES:

HLA-DRB1*03 is strongly associated with anti-Jo-1-positive idiopathic inflammatory myopathies (IIM) and there is now increasing evidence that Jo-1 antigen is preferentially expressed in lung tissue. This study examined whether smoking was associated with the development of anti-Jo-1 antibodies in HLA-DRB1*03-positive IIM.

METHODS:

IIM cases were selected with concurrent information regarding HLA-DRB1 status, smoking history and anti-Jo-1 antibody status. DNA was genotyped at DRB1 using a commercial sequence-specific oligonucleotide kit. Anti-Jo-1 antibody status was established using a line blot assay or immunoprecipitation.

RESULTS:

557 Caucasian IIM patients were recruited from Hungary (181), UK (99), Sweden (94) and Czech Republic (183). Smoking frequency was increased in anti-Jo-1-positive IIM cases, and reached statistical significance in Hungarian IIM (45% Jo-1-positive vs 17% Jo-1-negative, OR 3.94, 95% CI 1.53 to 9.89, p <0.0001). a=”a” strong=”strong” association=”association” between=”between” hla-drb1=”hla-drb1″ lang=”id_163″>

CONCLUSION:

Smoking appears to be associated with an increased risk of possession of anti-Jo-1 in HLA-DRB1*03-positive IIM cases. The authors hypothesise that an interaction between HLA-DRB1*03 and smoking may prime the development of anti-Jo-1 antibodies.

Comments are closed.